Nachrichten zur Madrigal Pharmaceuticals Corp. Aktie

ARWR: Multiple Important Clinical Readouts in 2H26

By David Bautz, PhDNASDAQ: ARWRREAD THE FULL ARWR RESEARCH REPORTBusiness UpdateUpdate on REDEMPLO® LaunchArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) launched REDEMPLO…

Madrigal Pharmaceuticals: Barclays sieht 80 % Kurspotenzial bei dem Biotech!

Spezialisierung auf fortschrittliche Lebertherapien Madrigal Pharmaceuticals (MDGL) ist ein biopharmazeutisches Unternehmen, das sich vollumfänglich auf die Entwicklung neuartiger Therapeutika für...…

What to Expect From These Drug/Biotech Players This Earnings Season?

Lets take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they…

MDGL Secures Exclusive Global Right for MASH Treatment From PFE

Madrigal Pharmaceuticals obtains global rights to Pfizers ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for…

Madrigal Pharmaceuticals: Rezdiffras US And EU Rollout Remains Promising

…

Madrigal Pharmaceuticals - Steigende Absätze bei Rezdiffra sorgen für Schwung!

Geschäftstreiber: Madrigal Pharmaceuticals ist ein US-Biopharmaunternehmen, das sich auf Therapien zur Behandlung von MASH spezialisiert. Mit Rezdiffra (Resmetirom) verfügt man…

Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term

…

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years

Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns. However, with hundreds…

Why Madrigal Pharmaceuticals Stock Is Soaring Today

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain…

Madrigal Pharmaceuticals Aktie: Blockbuster-Potenzial und frische Übernahmespekulationen

Kulmbach (www.aktiencheck.de) - Madrigal Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Madrigal…

Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH

…

Why Madrigal Pharmaceuticals Stock Was Plummeting This Week

An estimates-beating set of preliminary financial numbers and two bullish analyst updates werent enough to lift Madrigal Pharmaceuticals (NASDAQ: MDGL)…

Why Madrigal Pharmaceuticals Stock Is Sinking Today

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. The sell-off came…

Madrigal Pharmaceuticals director Fred Craves sells shares worth $1.14 million By Investing.com

Madrigal Pharmaceuticals director Fred Craves sells shares worth $1.14 million…

Arrowhead Pharma und Madrigal gehen steil: Zwischen Adipositas- und Übernahmefantasie

Die Biotechnologie-Branche bietet viele spannende Storys. Einen aussichtsreichen Aktienkorb mit 14 verschiedenen Titeln bildet der Biotech Supertrends Index ab. Zuletzt…

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

When a companys shares shoot up 82% in 12 months, investors clearly think its a good time to be a…

Madrigal Pharmaceuticals gains amid takeover speculation

…

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

…

AKTIONÄR-Hot-Stock Madrigal Pharmaceuticals: Top-News – Aktie gewinnt 19 Prozent

Die Aktie des US-Biotech-Unternehmens Madrigal Pharmaceuticals kann am heutigen Handelstag einen satten Kurssprung hinlegen. Damit konnte nicht nur die jüngste…

AKTIONÄR-Hot-Stock Madrigal Pharmaceuticals: Top-News – Aktie gewinnt 19 Prozent

Die Aktie des US-Biotech-Unternehmens Madrigal Pharmaceuticals kann am heutigen Handelstag einen satten Kurssprung hinlegen. Damit konnte nicht nur die jüngste…

Madrigal Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation

…

Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings

…

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will…

Is Madrigal Pharmaceuticals Stock a Buy?

The biotech could be worth a lot more in 10 years.…

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering…

Is Madrigal Pharmaceuticals a Millionaire Maker?

Its revenue ramp-up is just starting, and its market looks lucrative.…

Is Madrigal Pharmaceuticals Stock a Buy?

The company could become a prominent player in the biotech industry, but that might take a while.…

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.

Eli Lilly just drizzled on Madrigal Pharmaceuticals parade.…

Madrigal Pharmaceuticals senior VP sells $570,000 in stock By Investing.com

Madrigal Pharmaceuticals senior VP sells $570,000 in stock…

Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked

…

AKTIONÄR-Hot-Stock Madrigal Pharmaceuticals: Aktie mit Kurssprung – was ist da los?

Die Aktie des US-Biotech-Unternehmens Madrigal Pharmaceuticals entwickelt sich seit der Empfehlung des AKTIONÄR in der Rubrik „Hot-Stock der Woche“ in…

AKTIONÄR-Hot-Stock Madrigal Pharmaceuticals: Aktie mit Kurssprung – was ist da los?

Die Aktie des US-Biotech-Unternehmens Madrigal Pharmaceuticals entwickelt sich seit der Empfehlung des AKTIONÄR in der Rubrik „Hot-Stock der Woche“ in…

Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company…

Is Madrigal Pharmaceuticals Stock a Buy?

Its not the most prominent biotech, but it has an important claim to fame.…

Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript

…

US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Excitement grows as the FDAs first approval for MASH treatment nears commercialization, according to Spherix Global Insights. Excitement grows as…

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics

These businesses should see good times ahead.…

Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals

Both stocks are pretty risky, but one of them more so than the other.…

Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? @themotleyfool #stocks $MDGL

Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?…

Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?

Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?…

Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming

Drugmakers are racing to catch up to Madrigal Pharmaceuticals, which has the first drug for NASH liver disease. Meanwhile, AI…

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?

Madrigal has one key advantage over its two huge potential future rivals.…

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? @themotleyfool #stocks $MDGL $NVO $LLY

Madrigal has one key advantage over its two huge potential future rivals.…

dpa-AFX ProFeed